focus -WSS

focus

author：entertainment 2025-09-03 09:25:34 - browse：7897

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： CVS is willing to dump 10% of its Medicare Advantage members

focus

WSS

Cherokee Nation medical school graduates its first class

Obesity drug from Roche shows promise in early study

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Hottest summer in 2,000 years puts focus on extreme heat, health

CVS is willing to dump 10% of its Medicare Advantage members

Cherokee Nation medical school graduates its first class

knowledge

focus

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Abbott's new stent may help patients with peripheral artery disease

Medicare details structure of new drug price negotiation program

The United States must get value

Hepatitis C has a cure — but many Americans still lack access to it

The United States must get value

Tori Bowie and the unacceptable rates of Black maternal death

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

How to save PrEP access — and even expand it

Oak Street deal isn't the answer to health care's woes

hotspot

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

STAT reporters are Pulitzer Prize finalists for investigative reporting

As H5N1 spreads in cows, experts warn against drinking raw milk

STAT reporters are Pulitzer Prize finalists for investigative reporting

The United States must get value

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

explore

knowledge

focus

leisure time